FDA official announcements and Johnson & Johnson press releases

Johnson & Johnson's Seltorexant Succeeds in Late-Stage Study for Depression and Insomnia

May 29, 2024, 03:28 PM

Johnson & Johnson announced on Wednesday that its experimental drug, seltorexant, has met all primary and secondary goals in a late-stage study. The study evaluated the drug's effectiveness in patients with major depressive disorder (MDD) and insomnia symptoms. According to the company statement, seltorexant was successful in reducing symptoms of depression and improving sleep. This marks a significant advancement in the treatment of MDD, addressing both depression and insomnia symptoms.